IDEAYA Biosciences, Inc. 8-K

What Happened

• On May 5, 2026, IDEAYA Biosciences, Inc. announced it filed an automatic shelf registration statement on Form S-3ASR (Registration No. 333-295560) to replace its prior Form S-3 (which was scheduled to expire June 26, 2026). The prior registration was deemed terminated under Rule 415(a)(6) as of the new registration’s effectiveness on May 5, 2026.
• On the same date the company also filed an ATM prospectus supplement under its January 19, 2024 Open Market Sales Agreement with Jefferies LLC. The prospectus allows IDEAYA, at its discretion, to offer and sell shares of common stock with aggregate gross proceeds of up to $156.6 million — the remaining capacity under the Sales Agreement. Prior to termination of the prior registration, the company had sold $193,447,003.19 in common stock under the Sales Agreement, leaving $156,552,996.81 available. Latham & Watkins LLP issued a legal opinion related to the offering (filed as Exhibit 5.1).

Key Details

• Filing date: May 5, 2026 (Form S-3ASR and ATM prospectus supplement).
• ATM capacity remaining: $156,552,996.81 (reported as $156.6M).
• Prior gross sales under Sales Agreement: $193,447,003.19.
• Sales agent: Jefferies LLC; legal opinion and consent provided by Latham & Watkins LLP.

Why It Matters

• The new shelf registration and ATM prospectus give IDEAYA funding flexibility: the company can sell shares over time through Jefferies up to the stated $156.6M without a separate new registration for each sale.
• If and when the company sells shares under the ATM, that would raise cash for operations or other uses but would increase shares outstanding and could dilute existing shareholders.
• The filing does not itself raise funds or obligate IDEAYA to sell shares; it simply re-establishes and documents the remaining capacity under the existing Sales Agreement.